Administration Matters: Successful Management of Ticagrelor Resistance Challenges in a High-Risk Patient
This case report details the successful management of a high-risk patient with apparent ticagrelor resistance, evidenced by rising PRU levels despite adherence, through the strategic transition to a cangrelor infusion prior to a critical neurointerventional procedure.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the delicate world of preventing blood clots, doctors often rely on a class of medicines that act as a brake on the body's clotting system. These drugs, known as antiplatelets, stop blood cells called platelets from sticking together and forming dangerous blockages in arteries. One such drug, ticagrelor, is frequently chosen because it works quickly and reliably for many people. However, the human body is complex, and sometimes these medicines do not work as expected. This can happen if the body cannot absorb the drug properly, or if the patient's unique biology prevents the medication from becoming active. When a patient faces a high-risk procedure, such as a delicate surgery to repair a blood vessel in the brain, the failure of these drugs to do their job can lead to life-threatening complications. Understanding why a medicine might fail, and finding a way to make it work, is a critical challenge for modern medicine.
This story begins with a thirty-three-year-old woman from South Asia who arrived at a hospital facing a series of serious medical hurdles. She had recently suffered a stroke caused by a tear in a major artery in her neck, a condition that had also left her unable to swallow safely. To help her eat, doctors had placed a feeding tube directly into her stomach. She was now preparing for a planned procedure to fix a new tear in the same artery on the other side, a repair that required her blood to be thin enough to prevent clots but not so thin that she would bleed uncontrollably. To prepare, she had been taking aspirin and ticagrelor for two weeks. Despite her reported adherence to the regimen, tests taken just before her surgery showed that her blood was not responding to the medication as it should have. The test, which measures how much the drug is slowing down her platelets, showed a level that was barely within the safe range. Concerned that the drug might fail during the critical surgery, the medical team gave her an extra dose. Surprisingly, this extra dose made her blood's response even weaker, suggesting that the problem was not just a matter of dosage, but of how her body was handling the medicine.
The medical team, led by specialists at Riverside Methodist Hospital, began to investigate the root cause of this unexpected resistance. They considered that the patient's history of swallowing difficulties and the presence of a feeding tube might be interfering with how the drug moved through her system. While ticagrelor is designed to be absorbed in the small intestine, the journey there can be delayed if the stomach empties too slowly. The team realized that her condition might be keeping the drug in her stomach too long, preventing it from reaching the part of the gut where it could be absorbed. They also considered a different possibility: that her body might not be able to process a different, older drug often used as an alternative. However, testing for this specific genetic trait was not available, and the team suspected that her background might make her more likely to have such a genetic variation, making the switch risky. Instead of giving up on ticagrelor, they decided to change how the drug was delivered.
The solution involved two practical adjustments to the way the medication was given. First, the team crushed the ticagrelor tablet into a fine powder. This simple change allowed the drug to dissolve much faster and reach the small intestine more quickly, bypassing the slow dissolution that happens with a whole pill. Second, they introduced a medication called metoclopramide, which helps the stomach empty its contents faster. By giving this drug thirty minutes before the crushed ticagrelor, they aimed to push the medicine through the stomach and into the intestine before it could be degraded by stomach acid. The team administered the crushed ticagrelor through her feeding tube, but with a crucial difference: they did not hold back her nutrition, as they wanted to see how the drug would work under the same conditions she would face once she went home.
The results of this new approach were immediate and clear. Two hours after the crushed tablet was given, a follow-up test showed that her blood was responding exactly as needed, with the platelet activity dropping to a safe level. To ensure this was not a fluke, the team repeated the process. They gave her another dose of the crushed medication, again paired with the stomach-moving drug, and checked her levels at different times. The tests confirmed that her blood was consistently responding to the treatment. The team concluded that the initial failure was not because her body was immune to the drug, but because the way she was swallowing and digesting had prevented the drug from reaching its target. By adjusting the physical form of the pill and speeding up her digestion, they unlocked the drug's full potential.
This case offers a valuable lesson for managing patients who face similar high-risk situations. It suggests that when a standard dose of ticagrelor does not work, the issue may often be related to absorption rather than a fundamental resistance to the drug itself. For patients with swallowing difficulties, feeding tubes, or conditions that slow down digestion, crushing the tablet and using medications to speed up stomach emptying can be a highly effective strategy. The study also highlights the importance of timing when testing how well these drugs are working; checking the levels too soon after a crushed dose might give a false reading, while waiting the correct amount of time reveals the true effect. Ultimately, this approach allowed a high-risk patient to undergo a necessary procedure safely, demonstrating that sometimes the key to a medicine's success lies not in changing the drug, but in changing how it is delivered.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.